Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma
Conditions
Interventions
Beclomethasone dipropionate BAI
Placebo BAI
+3 more
Locations
102
United States
Teva Investigational Site 12346
Hoover, Alabama, United States
Teva Investigational Site 12294
Montgomery, Alabama, United States
Teva Investigational Site 10925
Phoenix, Arizona, United States
Teva Investigational Site 12349
Little Rock, Arkansas, United States
Teva Investigational Site 10903
Costa Mesa, California, United States
Teva Investigational Site 10911
Downey, California, United States
Start Date
December 1, 2013
Primary Completion Date
February 1, 2016
Completion Date
March 1, 2016
Last Updated
November 9, 2021
NCT07431021
NCT07383896
NCT07282886
NCT07356310
NCT06003569
NCT05562466
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions